Oxford professor, Islamic scholar Tariq Ramadan held in France on rape charge

Agencies
February 3, 2018

Paris, Feb 3: Tariq Ramadan, a prominent Swiss academic and renowned professor of contemporary Islamic studies at the University of Oxford, was charged in France with rape on Friday, based on accusations made against him four months ago by two women.

The 55-year-old theologian and philosopher, was placed under formal investigation on charges of rape and rape of a vulnerable person, according to a spokesman for the French judiciary. He was taken into custody on Wednesday as part of a preliminary inquiry in Paris.

Ramadan, a Swiss citizen is also the grandson of Hassan al-Banna, the founder of Egypt’s Muslim Brotherhood movement. A regular face on French television, he is the most prominent figure to be held in France after the women, emboldened by the #MeToo campaign to stamp out sexual assault and harassment, went to the police. According to those two women, Ramadan violently assaulted them in hotel rooms in Lyon and Paris in 2009 and 2012 after conferences.

The professor – who made his name as an author and commentator on modern Islam, as well as advising successive British governments on Islam and society – has denied the separate accusations by the two women.

After two days of questioning Ramadan, who is married with four children, was brought before three magistrates who have been assigned to the case, suggesting that he is facing an extensive investigation, judicial sources told AFP. In the full investigation opened this week, French magistrates must establish whether he should stand trial.

The first police complaint against Ramadan was made by Henda Ayari, 41, a feminist activist who previously practised a conservative strain of Islam and now heads the women’s organisation Les Libératrices.

She filed a complaint with prosecutors in Rouen in October 2017 alleging rape, sexual violence, harassment and intimidation by Ramadan. She said she was assaulted by him in a Paris hotel room after a conference in 2012.

“He choked me so hard that I thought I was going to die,” she told Le Parisien newspaper. “He slapped me because I resisted. He raped me. I felt I was in extreme danger.” She said she had gone to talk to him at his hotel after the conference as a kind of “big brother figure”.

Ayari had described the rape in a chapter of her 2016 book, I Chose to be Free, giving her assailant a made-up name and saying that an intellectual had attacked her in a hotel room. She fought back but was insulted, slapped and treated violently, she wrote.

After the Harvey Weinstein sexual assault and harassment scandal broke in the autumn of 2017 Ayari said she had decided to go public and name Ramadan. She made a formal complaint on October 20.

A few days later an anonymous disabled woman, a Muslim convert, accused the academic of raping and violently assaulting her in a hotel room in the south-eastern city of Lyon in 2009.

The French edition of Vanity Fair magazine, whose staff met the 45-year-old woman, said her lawsuit against Ramadan described “blows to the face and body, forced sodomy, rape with an object and various humiliations, including being dragged by the hair to the bathtub and urinated on”.

The woman said Ramadan had asked to meet her in the bar of the Hilton hotel in Lyon, where he was taking part in a conference in 2009. She had previously been in contact with him online for some months, seeking advice.

In online messages and chats, Ramadan had told the woman he was living separately from his wife, the French newspaper Le Monde reported.

In the hotel bar Ramadan had complained that people had recognised him and were staring at him, suggesting they instead go to his room. He took the stairs while the woman, who walks with a crutch after a car accident, took the lift. The woman said she was attacked very soon after entering the room, sustaining blows to the face, arms, breasts and stomach before being repeatedly raped.

During three hours of testimony in Paris on Thursday, the woman — referred to in the media by the pseudonym “Christelle” — recounted her allegations to the judge in Ramadan’s presence.

Rejecting her testimony outright, Ramadan refused to sign the official summary of the account, sources close to the case said. “Both sides maintained their positions,” a legal source said.

Eric Morain, Christelle’s lawyer, said the charges were “an important step” after what he called “a painstaking three-month investigation, 48 hours of police questioning and a confrontation with my client”.

Police have interviewed dozens of people close to both Ramadan and the two women, and examined email and social media exchanges between them.

Ramadan, a senior research fellow of St Antony’s College, took leave of absence from Oxford University last November “by mutual agreement” after the two women filed complaints.

He continues to head the Islamic Institute for Ethical Training in France. Ayari was placed under police protection in November after receiving death threats.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 30,2020

New Delhi, May 30: The COVID-19 pandemic has left the Indian private healthcare sector in acute financial distress, a new survey said on Friday adding that the healthcare facilities in the country have witnessed at least 80 per cent fall in average revenue.

Post the lockdown from March 24, Indian hospitals have seen a large impact, especially among small and medium-sized hospitals, which are now facing existential challenges.

The survey by healthcare industry body NATHEALTH was conducted in 251 healthcare facilities across nine states and 69 cities to assess the impact of COVID-19 on the domestic healthcare industry.

The findings showed that 90 per cent of the surveyed healthcare facilities are facing financial challenges with 21 per cent facilities facing an existential threat.

"There is a need for a stimulus package to revive the Indian healthcare industry which will be crucial to provide much-needed relief to the healthcare sector which is the frontline defence in this fight against COVID-19," said Dr Sudarshan Ballal, President NATHEALTH.

According to the survey, hospitals in tier 1 and tier 2 cities are experiencing a 78 per cent reduction in OPD footfalls, and a drop of 79 per cent in in-patient admissions.

The study found that 90 per cent of organisations require some form of financial assistance.

The findings indicated that even after the lockdown lift, the situation will remain difficult for the hospitals and nursing homes as patients will hesitate from visiting hospitals.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 12,2020

Jun 12: The global number of COVID-19 cases has increased to over 7.5 million, while the death toll was nearing 421,000, according to the Johns Hopkins University.

As of Friday morning, the overall number of cases stood at 7,500,777, while the deaths increased to 420,993, the University's Center for Systems Science and Engineering (CSSE) revealed in its latest update.

The US continues with the world's highest number of confirmed cases and deaths at 2,022,488 and 113,803, respectively, according to the CSSE.

In terms of cases, Brazil comes in the second place with 802,828 infections.

This was followed by Russia (501,800), the UK (292,860), India (286,605), Spain (242,707), Italy (236,142), Peru (214,788), France (192,493), Germany (186,691), Iran (180,156), Turkey (174,023), Chile (154,092), Mexico (133,974), Pakistan (125,933) and Saudi Arabia (116,021), the CSSE figures showed.

Regarding fatalities, the UK continues in the second position after the US with 41,364 COVID-19 deaths, which also accounts for the highest number of fatalities in Europe.

The other countries with over 10,000 deaths are Brazil (40,919), Italy (34,167), France (29,349), Spain (27,136) and Mexico (15,944).

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.